We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.
Lynkuet dosage · All 50 States
Lynkuet (elinzanetant) dosage: once daily at bedtime, liver tests before treatment and at month 3, sleepiness precautions and CYP3A interactions.
Start your visit →← Hormone replacement therapy pillar
DIRECT ANSWER
Lynkuet is taken once daily at bedtime at a fixed labeled dose — there is no titration. Because it can cause sleepiness and next-day impairment, bedtime dosing is required and you should not drive until you know how it affects you. Liver tests are checked before starting and again at month 3. Strong CYP3A inhibitors and some other medicines interact with it.
| Strength / step | How it is used | Labeled detail | When clinicians use it | Watch for |
|---|---|---|---|---|
| Fixed labeled dose, once at bedtime | Capsules, nightly | Per current label | Moderate-to-severe menopausal hot flashes | Sleepiness or next-day impairment |
| Baseline liver tests | Before first dose | Required | Everyone | Abnormal results need review |
| Month 3 transaminases | Follow-up liver test | Per current label | Everyone on treatment | Lab visit needed |
Strengths shown are from current U.S. labeling, for context only. Your clinician sets your dose based on your history.
RxNorm is the U.S. National Library of Medicine's standard naming system for medicines. These codes link each product to its official record.
The label directs bedtime dosing because of sleepiness.
The label describes a single fixed dose. Your clinician will advise if interactions change whether it is appropriate.
No. It blocks NK1 and NK3 receptors in the brain.
A board-certified clinician licensed in your state reviews your intake within one business day and recommends the route that fits your history — not a template.
Start your visit →Comparing providers first? How to choose an HRT telehealth provider →
WRITTEN & MEDICALLY REVIEWED BY
Kindr Health Inc. — Editorial & Clinical Team, led by Kevin Wolfe, CMO
Kindr’s clinical content is written and reviewed by board-certified clinicians who prescribe hormone therapy every day across all 50 states — menopause-focused physicians, nurse practitioners, and pharmacists working under Kindr Health, Inc.’s organizational clinical oversight. Every page is checked against current NAMS and ACOG guidance, FDA labeling, and the primary literature before publication, then re-reviewed on a rolling schedule when guidance changes.
Organizational NPI 1609792902 · Last reviewed July 3, 2026 · Editorial policy
Educational content only — not a substitute for individual medical advice, diagnosis, or treatment.
SOURCES & REFERENCES
Information on this page is for educational purposes only. Prescription medications require clinical evaluation and provider approval. Individual results vary. Not an emergency service.